Long-Term Survival of a Patient with Glioblastoma Multiforme

Authors

  • Radwa M hamed Radiation Oncology Department, International medical center (IMC), Cairo, Egypt. Author
  • Abdelmonem N Hamad Radiation Oncology Department, maadi Armed Forces Medical Compound, Cairo, Egypt. Author
  • Adel H Hassan Radiation Oncology Department, maadi Armed Forces Medical Compound, Cairo, Egypt. Author
  • HS Attalah Head of Radiation Oncology Department, International medical center (IMC), Cairo, Egypt. Author

DOI:

https://doi.org/10.47363/JCRR/2020(2)108

Keywords:

Survival, Patient, Glioblastoma Multiforme

Abstract

Glioblastoma multiforme (GBM) remains the most aggressive brain tumor in adults despite the advances in diagnosis and treatment over the past few decades[1]. Standard treatment for patients with newly diagnosed GBM consists of maximal safe resection followed by postoperative radiation with concomitant and adjuvant temozolomide [2]. Despite that, recurrence is common and the prognosis remains poor with a median survival of 12–15 months [3].

Author Biographies

  • Radwa M hamed, Radiation Oncology Department, International medical center (IMC), Cairo, Egypt.

    Radiation Oncology Department, International medical center (IMC), Cairo, Egypt.

  • Abdelmonem N Hamad, Radiation Oncology Department, maadi Armed Forces Medical Compound, Cairo, Egypt.

    Radiation Oncology Department, maadi Armed Forces Medical Compound, Cairo, Egypt.

  • Adel H Hassan, Radiation Oncology Department, maadi Armed Forces Medical Compound, Cairo, Egypt.

    Radiation Oncology Department, maadi Armed Forces Medical Compound, Cairo, Egypt.

  • HS Attalah, Head of Radiation Oncology Department, International medical center (IMC), Cairo, Egypt.

    Head of Radiation Oncology Department, International medical center (IMC), Cairo, Egypt .

Downloads

Published

2020-07-29

Issue

Vol. 2 No. 2 (2020): Volume 2 Issue 2

Section

Articles